Across TCGA pan-cancer cohorts, GOLGA6L9 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated GOLGA6L9 data layer compared with 1 for mutation status.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher GOLGA6L9 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated GOLGA6L9 expression acts as an unfavorable survival marker, although some lineages such as SKCM and BLCA show a favorable association.
KIRC, KICH, and UVM are the cancer types where GOLGA6L9 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.